Skip to main content
Home
FULL MENU Close Menu
Home
Home

Jennifer Smith

Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.

Article

New appointments at City of Hope, UA, and Fox Chase

Author:
Jennifer Smith
Publish date: July 15, 2019

The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an...

  • Read More

Article

Endoscopic treatment effective in T1b esophageal cancer

Author:
Jennifer Smith
Publish date: July 11, 2019

A systematic review suggests endoscopic treatment is appropriate for T1b esophageal cancers with a low risk of metastasis.

  • Read More

Video

SC daratumumab deemed feasible for every multiple myeloma patient

Author:
Jennifer Smith
Publish date: July 11, 2019

CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...

  • Read More

News

CNS-directed therapy appears more effective for synDLBCL

Author:
Jennifer Smith
Publish date: July 9, 2019

Two-year survival rates were superior among patients who received CNS-intensive therapy.

  • Read More

Article

Hemostasis researcher passes away at age 72

Author:
Jennifer Smith
Publish date: July 1, 2019

Dr. George J. Broze, who is known for his research on hemostasis and the relationship between coagulation and inflammation, died following a heart...

  • Read More

News

‘Robust antitumor immune responses’ observed in pediatric ALL

Author:
Jennifer Smith
Publish date: June 26, 2019

Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL...

  • Read More

News

BET inhibitors may target oncogene in ABC-like DLBCL

Author:
Jennifer Smith
Publish date: June 21, 2019

Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.

  • Read More

News

‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL

Author:
Jennifer Smith
Publish date: June 17, 2019

CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.

  • Read More

Article

Stand Up To Cancer adds research muscle

Author:
Jennifer Smith
Publish date: June 17, 2019

Dr. John D. Carpten and Dr. Roderic I. Pettigrew have joined the Stand Up To Cancer scientific advisory committee. And Fox Chase Cancer Center in...

  • Read More

News

R2 appears active in high-risk FL and MZL

Author:
Jennifer Smith
Publish date: June 14, 2019

CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.

  • Read More

News

Triplet offers longest PFS yet seen in relapsed/refractory myeloma

Author:
Jennifer Smith
Publish date: June 12, 2019

CHICAGO – Patients who received isatuximab plus pomalidomide and dexamethasone had a median progression-free survival of 11.53 months.

  • Read More

News

Four-drug combo bests triplet in newly diagnosed myeloma

Author:
Jennifer Smith
Publish date: June 12, 2019

CHICAGO – Results with daratumumab plus bortezomib, thalidomide, and dexamethasone are the “best ever reported in the setting of stem cell...

  • Read More

News

Adding ipilimumab to nivolumab provides no benefit in SCC trial

Author:
Jennifer Smith
Publish date: June 12, 2019

CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...

  • Read More

News

Pregnancy deemed safe in BRCA-mutated breast cancer survivors

Author:
Jennifer Smith
Publish date: June 11, 2019

Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.

  • Read More

News

Inhibitor produces high response rate in relapsed/refractory FL

Author:
Jennifer Smith
Publish date: June 11, 2019

CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...

  • Read More

Pages

  • « first
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close